Timing of anticoagulation therapy in patients with acute ischaemic stroke and atrial fibrillation

Maurizio Paciaroni; Giancarlo Agnelli; Walter Ageno; Valeria Caso

doi:10.1160/TH16-03-0217

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2016; 116(03): 410-416
DOI: 10.1160/TH16-03-0217

Review Article

Schattauer GmbH

Timing of anticoagulation therapy in patients with acute ischaemic stroke and atrial fibrillation

Authors

Maurizio Paciaroni

¹Stroke Unit and Division of Cardiovascular Medicine, University of Perugia, Italy
Giancarlo Agnelli

¹Stroke Unit and Division of Cardiovascular Medicine, University of Perugia, Italy
Walter Ageno

²Department of Internal Medicine, Insubria University, Varese, Italy
Valeria Caso

¹Stroke Unit and Division of Cardiovascular Medicine, University of Perugia, Italy

Abstract

Summary

In patients with acute stroke and atrial fibrillation (AF), the risk of early recurrence has been reported to range between 0.1% and 1.3% per day. Anticoagulants are the most effective therapy for the prevention of recurrent ischaemic stroke in these patients, but randomised clinical trials have failed to produce any evidence supporting the administration of heparin within 48 hours from stroke onset as it has been associated with a non-significant reduction in the recurrence of ischaemic stroke, no substantial reduction in death and disability, and an increase in intracranial bleeding. As early haemorrhagic transformation is a major concern in the acute phase of stroke patients with AF, determining the optimal time to start anticoagulant therapy is essential. This review which focuses on the epidemiology of recurrent ischaemic stroke and haemorrhagic transformation in patients with acute ischaemic stroke and AF, proposes a model for decision making on optimal timing for initiating anticoagulation, based on currently available evidence.

Keywords

Atrial fibrillation - ischaemic stroke - secondary prevention - acute therapy

Full Text

References

References
1 Kernan WN, Ovbiagele B, Black HR. et al. American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischaemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014; 45: 2160-2236.
2 Saxena R, Lewis S, Berge E. et al. Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischaemic stroke and atrial fibrillation in the International Stroke Trial. Stroke 2001; 32: 2333-2337.
3 Paciaroni M, Agnelli G, Falocci N. et al. Early Recurrence and Cerebral Bleeding in Patients With Acute Ischaemic Stroke and Atrial Fibrillation: Effect of Anticoagulation and Its Timing: The RAF Study. Stroke 2015; 46: 2175-2182.
4 Paciaroni M, Agnelli G, Falocci N. et al. Prognostic value of trans-thoracic echocardiography in patients with acute stroke and atrial fibrillation: findings from the RAF study. J Neurol. 2015 Epub ahead of print.
5 Yaghi S, Moon YP, Mora-McLaughlin C. et al. Left atrial enlargement and stroke recurrence: the northern Manhattan stroke study. Stroke 2015; 46: 1488-1493.
6 De Bruijn SFTM, Agema WRP, Lammers GJ. et al. Transesophageal echocardiography is superior to transthoracic echocardiography in management of patients of any age with transient ischaemic attack or stroke. Stroke 2006; 37: 2531-2534.
7 Paciaroni M, Agnelli G, Corea F. et al. Early haemorrhagic transformation of brain infarction: rate, predictive factors, and influence on clinical outcome: results of a prospective multicenter study. Stroke 2008; 39: 2249-2256.
8 Marsh EB, Llinas RH, Hillis AE, Gottesman RF.. Haemorrhagic Transformation in Patients with Acute Ischaemic Stroke and an Indication for Anticoagulation. Eur J Neurol 2013; 20: 962-967.
9 Lip GY, Nieuwlaat R, Pisters R. et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137: 263-272.
10 Gubitz G, Sandercock P, Counsell C.. Anticoagulants for acute ischaemic stroke. Cochrane Database Syst Rev 2004; 3: CD000024.
11 Beri A, Punnam SR.. Anticoagulation in patients with acute ischaemic stroke and atrial fibrillation--a balance of risks and benefits. Cardiovasc Drugs Ther 2008; 22: 419-425.
12 Whiteley WN, Adams HPjr, Bath PM. et al. Targeted use of heparin, hepari-noids, or low-molecular-weight heparin to improve outcome after acute ischaemic stroke: an individual patient data meta-analysis of randomized controlled trials. Lancet Neurol 2013; 12: 539-545.
13 Berge E, Abdelnoor M, Nakstad PH. et al. Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomized study. Lancet 2000; 355: 1205-1210.
14 Paciaroni M, Agnelli G, Micheli S. et al. Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials. Stroke 2007; 38: 423-430.
15 Micheli S, Agnelli G, Caso V. et al. Clinical benefit of early anticoagulation in cardioembolic stroke. Cerebrovasc Dis 2008; 25: 289-296.
16 Abdul-Rahim AH, Fulton RL, Frank B. et al VISTA collaborators. Association of improved outcome in acute ischaemic stroke patients with atrial fibrillation who receive early antithrombotic therapy: analysis from VISTA. Eur J Neurol 2015; 22: 1048-1055.
17 Palm F, Kraus M, Safer A. et al. Management of oral anticoagulation after cardioembolic stroke and stroke survival data from a population based stroke registry (LuSSt). BMC Neurol 2014; 14: 199.
18 Chamorro A, Vila N, Ascaso C. et al. Heparin in acute stroke with atrial fibrillation: clinical relevance of very early treatment. Arch Neurol 1999; 56: 1098-1102.
19 Hahn C, Hill MD.. Early anti-coagulation after ischaemic stroke due to atrial fibrillation is safe and prevents recurrent stroke. Can J Neurol Sci 2015; 42: 92-95.
20 Hallevi H, Albright KC, Martin-Schild S. et al. Anticoagulation after cardioembolic stroke: to bridge or not to bridge?. Arch Neurol 2008; 65: 1169-1173.
21 Kim TH, Kim JY, Mun HS. et al. Heparin bridging in warfarin anticoagulation therapy initiation could increase bleeding in non-valvular atrial fibrillation patients: a multicenter propensity-matched analysis. J Thromb Haemost 2015; 13: 182-190.
22 Audebert HJ, Schenk B, Tietz V. et al. Initiation of oral anticoagulants after acute ischaemic stroke or transient ischaemic attack: timing and complications of overlapping heparin or conventional treatment. Cerebrovasc Dis 2008; 26: 171-177.
23 Connolly SJ, Ezekowitz MD, Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
24 Granger CB, Alexander JH, McMurray JJ. et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992.
25 Patel MR, Mahaffey KW, Garg J. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891.
26 Giugliano RP, Ruff CT, Braunwald E. et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093-2104.
27 Easton JD, Lopes RD, Bahit MC. et al. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol 2012; 11: 503-511.
28 Shibazaki K, Kimura K, Aoki J. et al. Early initiation of new oral anticoagulants in acute stroke and TIA patients with nonvalvular atrial fibrillation. J Neurol Sci 2013; 331: 90-93.
29 Nomura E, Ohshita T, Imamura E. et al. Early administration of non-vitamin K antagonist oral anticoagulants for acute ischaemic stroke patients with atrial fibrillation in comparison with warfarin mostly combined with heparin. Circ J 2015; 79: 862-866.
30 Ritzenthaler T, Derex L, Davenas C. et al. Safety of early initiation of rivaroxaban or dabigatran after thrombolysis in acute ischaemic stroke. Rev Neurol 2015; 171: 613-615.
31 Arihiro S, Todo K, Koga M. et al. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI- Nonvalvular Atrial Fibrillation (NVAF) study. Int J Stroke. 2016 Epub ahead of print.
32 Arnao V, Agnelli G, Paciaroni M.. Direct oral anticoagulants in the secondary prevention of stroke and transient ischaemic attack in patients with atrial fibrillation. Intern Emerg Med 2015; 10: 555-560.
33 Kate M, Gioia L, Buck B. et al. Dabigatran Therapy in Acute Ischaemic Stroke Patients Without Atrial Fibrillation. Stroke 2015; 46: 2685-2687.
34 Heidbuchel H, Verhamme P, Alings M. et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin k antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015; 17: 1467-1507.
35 Osranek M, Bursi F, Bailey KR. et al. Left atrial volume predicts cardiovascular events in patients originally diagnosed with lone atrial fibrillation: three-decade follow-up. Eur Heart J 2005; 26: 2556-2561.
36 Kim TW, Jung SW, Song IU. et al. Left atrial dilatation is associated with severe ischaemic stroke in men with nonvalvular atrial fibrillation. J Neurol Sci 2015; 354: 97-102.
37 Douen AG, Sabin M, Pageau N.. Thrombus detection by echocardiography in patients with acute ischaemic stroke and chronic or new-onset atrial fibrillation. J Stroke Cerebrovasc Dis 2008; 17: 208-211.
38 Sacco S, Marini C, Toni D. et al. Incidence and 10-year survival of intracerebral haemorrhage in a population-based registry. Stroke 2009; 40: 394-399.
39 Tatu L, Moulin T, Bogousslavsky J. et al. Arterial territories of the human brain: cerebral hemispheres. Neurology 1998; 50: 1699-1708.
40 Tatu L, Moulin T, Bogousslavsky J. et al. Arterial territories of the human brain: brainstem and cerebellum. Neurology 1996; 47: 1125-1135.